Insider Buying: NewAmsterdam Pharma (NASDAQ:NAMS) Director Purchases 1,260 Shares of Stock

Key Points

• Director James Topper of NewAmsterdam Pharma purchased 1,260 shares at an average price of $24.99, increasing his total ownership to 3,027,864 shares valued at approximately $75.67 million.
• The stock price of NewAmsterdam Pharma has recently increased, trading up 1.1% to $26.90, with a 12-month range between $14.06 and $27.29.
• Analyst ratings for NewAmsterdam Pharma are largely positive, with several firms maintaining buy ratings and a consensus price target of $41.55.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) Director James Topper acquired 1,260 shares of NewAmsterdam Pharma stock in a transaction dated Monday, September 8th. The shares were purchased at an average price of $24.99 per share, with a total value of $31,487.40. Following the acquisition, the director owned 3,027,864 shares of the company's stock, valued at approximately $75,666,321.36. This trade represents a 0.04% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

NewAmsterdam Pharma Trading Up 1.1%

Shares of NASDAQ:NAMS traded up $0.30 during trading on Wednesday, reaching $26.90. 1,158,119 shares of the stock were exchanged, compared to its average volume of 885,128. NewAmsterdam Pharma Company N.V. has a 12 month low of $14.06 and a 12 month high of $27.29. The firm has a market cap of $3.03 billion, a PE ratio of -16.60 and a beta of -0.01. The stock has a 50-day moving average price of $23.29 and a 200-day moving average price of $20.66.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.52) by $0.37. NewAmsterdam Pharma had a negative return on equity of 27.27% and a negative net margin of 259.07%.The company had revenue of $19.15 million during the quarter, compared to analysts' expectations of $1.44 million. On average, sell-side analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

NAMS has been the subject of several recent research reports. Needham & Company LLC reiterated a "buy" rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a research note on Thursday, June 12th. Stifel Nicolaus started coverage on shares of NewAmsterdam Pharma in a report on Tuesday, June 10th. They issued a "buy" rating and a $44.00 target price for the company. Wall Street Zen upgraded shares of NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a report on Saturday, July 5th. Citigroup assumed coverage on shares of NewAmsterdam Pharma in a report on Tuesday, June 17th. They set a "buy" rating and a $42.00 price target for the company. Finally, Royal Bank Of Canada increased their price objective on NewAmsterdam Pharma from $38.00 to $39.00 and gave the company an "outperform" rating in a report on Thursday, August 7th. Nine analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $41.55.

Institutional Investors Weigh In On NewAmsterdam Pharma

A number of hedge funds have recently made changes to their positions in NAMS. China Universal Asset Management Co. Ltd. raised its holdings in shares of NewAmsterdam Pharma by 2.4% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 22,549 shares of the company's stock worth $408,000 after purchasing an additional 521 shares during the period. Duquesne Family Office LLC increased its holdings in shares of NewAmsterdam Pharma by 4.0% in the second quarter. Duquesne Family Office LLC now owns 832,175 shares of the company's stock worth $15,071,000 after purchasing an additional 31,815 shares during the period. Exome Asset Management LLC bought a new position in shares of NewAmsterdam Pharma in the second quarter worth $662,000. Frazier Life Sciences Management L.P. lifted its stake in NewAmsterdam Pharma by 3.0% during the second quarter. Frazier Life Sciences Management L.P. now owns 16,607,074 shares of the company's stock worth $300,754,000 after purchasing an additional 490,656 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in NewAmsterdam Pharma by 4.5% in the second quarter. BNP Paribas Financial Markets now owns 29,277 shares of the company's stock worth $530,000 after buying an additional 1,257 shares in the last quarter. 89.89% of the stock is currently owned by institutional investors.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.